Comment
doi: 10.1016/j.it.2018.12.009.
Epub 2019 Jan 1.
Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board
Affiliations
- PMID: 30609967
- DOI: 10.1016/j.it.2018.12.009
Item in Clipboard
Comment
Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board
Trends Immunol.
2019 Feb.
Abstract
Antibodies directed towards checkpoint inhibitors have unveiled extraordinary potential in cancer therapy. An article by the Vivier group (Cell 2018;175:1731-1743) shows that blocking the HLA-E-specific NKG2A inhibitory receptor, expressed by NK and inducible in T cells, results in benefits against poor prognosis tumors. Moreover, NKG2A and PD-1/PD-L1 mAb combinations unleash tumor-specific T cell proliferation and memory.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Comment on
-
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.Cell. 2018 Dec 13;175(7):1731-1743.e13. doi: 10.1016/j.cell.2018.10.014. Epub 2018 Nov 29. Cell. 2018. PMID: 30503213 Free PMC article. Review.
Similar articles
-
Enhancing Natural Killer and CD8+ T Cell-Mediated Anticancer Cytotoxicity and Proliferation of CD8+ T Cells with HLA-E Monospecific Monoclonal Antibodies.Monoclon Antib Immunodiagn Immunother. 2019 Apr;38(2):38-59. doi: 10.1089/mab.2018.0043. Monoclon Antib Immunodiagn Immunother. 2019. PMID: 31009335 Free PMC article. Review.
-
HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cells.Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1172-7. doi: 10.1073/pnas.95.3.1172. Proc Natl Acad Sci U S A. 1998. PMID: 9448304 Free PMC article.
-
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells.Haematologica. 2016 May;101(5):626-33. doi: 10.3324/haematol.2015.135301. Epub 2015 Dec 31. Haematologica. 2016. PMID: 26721894 Free PMC article.
-
Differential expression of natural killer cell receptors (CD94/NKG2A) on T cells by the stimulation of G-CSF-mobilized peripheral blood mononuclear cells with anti-CD3 monoclonal antibody and cytokines: a study in stem cell donors.Transplant Proc. 2004 Oct;36(8):2511-2. doi: 10.1016/j.transproceed.2004.08.044. Transplant Proc. 2004. PMID: 15561299
-
TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.Immunol Rev. 2017 Mar;276(1):112-120. doi: 10.1111/imr.12518. Immunol Rev. 2017. PMID: 28258695 Review.
Cited by
-
Targeting Natural Killer Cells for Tumor Immunotherapy.Front Immunol. 2020 Feb 19;11:60. doi: 10.3389/fimmu.2020.00060. eCollection 2020. Front Immunol. 2020. PMID: 32140153 Free PMC article. Review.
-
Exploiting Human NK Cells in Tumor Therapy.Front Immunol. 2020 Jan 17;10:3013. doi: 10.3389/fimmu.2019.03013. eCollection 2019. Front Immunol. 2020. PMID: 32010130 Free PMC article. Review.
-
Helper Innate Lymphoid Cells in Human Tumors: A Double-Edged Sword?Front Immunol. 2020 Jan 29;10:3140. doi: 10.3389/fimmu.2019.03140. eCollection 2019. Front Immunol. 2020. PMID: 32063901 Free PMC article. Review.
-
NKG2A Immune Checkpoint in Vδ2 T Cells: Emerging Application in Cancer Immunotherapy.Cancers (Basel). 2023 Feb 16;15(4):1264. doi: 10.3390/cancers15041264. Cancers (Basel). 2023. PMID: 36831606 Free PMC article. Review.
-
Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation.Front Immunol. 2019 May 28;10:1179. doi: 10.3389/fimmu.2019.01179. eCollection 2019. Front Immunol. 2019. PMID: 31231370 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
